BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today…
Author: Business Wire
Alcon to Highlight Robust Scientific Program Showcasing Latest Innovations at Virtual American Society of Cataract and Refractive Surgery 2020 Annual Meeting
FORT WORTH, Texas–(BUSINESS WIRE)–Alcon to Highlight Robust Scientific Program Showcasing Latest Innovations at Virtual ASCRS 2020
Alcon to Highlight Robust Scientific Program Showcasing Latest Innovations at Virtual American Society of Cataract and Refractive Surgery 2020 Annual Meeting
FORT WORTH, Texas–(BUSINESS WIRE)–Alcon to Highlight Robust Scientific Program Showcasing Latest Innovations at Virtual ASCRS 2020
U.S. Physician Survey Illustrates the Devastating Impact of Thyroid Eye Disease on Patient Quality of Life
DUBLIN–(BUSINESS WIRE)–Horizon announces a U.S. physician survey illustrating the devastating impact of Thyroid Eye Disease (TED) on patient quality of life.
VisionCare, Inc. Announces CE Mark Approval of the Tsert-SI™ Delivery System for the CentraSight Treatment Program
SARATOGA, Calif.–(BUSINESS WIRE)–VisionCare, Inc. announces that receipt of a Conformité Européene (CE) Mark for the Tsert-SI™ delivery system for the CentraSight treatment program
Global Dry Eye Market, Pipeline, Epidemiology, Competitive Analysis, Drug Sales and Shares (2016-2024) – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Dry Eye Market and Competitive Landscape – 2020” report has been added to ResearchAndMarkets.com’s offering. This research report provides comprehensive insights into the Dry Eye pipeline, epidemiology, market valua…
Dyno Therapeutics Announces Ocular Collaboration with Novartis to Develop Improved Gene Therapies with AAV Vectors based on AI Technology
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dyno Therapeutics Announces Ocular Collaboration with Novartis to Develop Improved Gene Therapies with AAV Vectors based on AI Technology
Ocular Therapeutix™ To Present New Data at the American Society of Cataract and Refractive Surgery (ASCRS) 2020 Virtual Annual Meeting
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announc…
jCyte Inc. Enters into Ex-US Licensing and Commercialization Agreement for jCell Therapy with Global Ophthalmology Leader Santen Pharmaceutical
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–jCyte Inc. Enters into Ex-US Licensing and Commercialization Agreement for jCell Therapy with Global Ophthalmology Leader Santen Pharmaceutical
Ocular Therapeutix™ Reports First Quarter 2020 Financial Results and Business Update
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today…
Global Pipeline Drug Forecasts for Age-Related Macular Degeneration – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2028” report has been added to ResearchAndMarkets.com’s offering. Age-related macular degeneration (AMD) is an eye condition that is characteriz…
National Vision Holdings, Inc. Announces Pricing of Private Offering of $350 Million Aggregate Principal Amount of 2.50% Convertible Senior Notes due 2025
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (the “Company”) today announced the pricing of a private offering of $350.0 million aggregate principal amount of 2.50% Convertible Senior Notes due 2025 (the “Notes”), to be so…
Glaukos Corporation Announces First Quarter 2020 Financial Results
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced finan…
Lineage Cell Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #AMD–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today reported financial and operating res…
Eurofins Technologies bringt Multiplex-Echtzeit-PCR-Test zum Nachweis von SARS-CoV-2-Viren (Coronaviren) heraus
LUXEMBURG–(BUSINESS WIRE)–Regulatory News: Eurofins Technologies (Paris: ERF) meldet die Verfügbarkeit seines CE-IVD-gekennzeichneten Multiplex-Echtzeit-RT-PCR-Tests (RT-PCR = Reverse-Transkriptase-Polymerase-Kettenreaktion) für den direkten qualitat…
Lineage Cell Therapeutics Announces Early Exercise of Option with Cancer Research UK for Immuno-Oncology Cell Therapy Program
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #AMD–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Cancer Research UK’s …
CORRECTING and REPLACING National Vision Holdings, Inc. Reports First Quarter 2020 Financial Results
DULUTH, Ga.–(BUSINESS WIRE)–First sentence of “Conference Call Details” section should read: “…May 7, 2020, at 8:00 a.m. Eastern Time” (insead of “…May 7, 2020, at 10:00 a.m. Eastern Time”). The corrected release reads: NATIONAL VISION HOLDINGS, …
Eurofins Technologies lance un essai PCR multiplex en temps réel pour la détection du pathogène du SARS-CoV-2 (Coronavirus)
LUXEMBOURG–(BUSINESS WIRE)–Eurofins Technologies (Paris:ERF) annonce le lancement de son essai RT-PCR (réaction en chaîne de la polymérase à la transcriptase inverse) en temps réel multiplex marqué CE-IVD pour la détection directe qualitative du path…
Aldeyra Therapeutics Reports First-Quarter 2020 Financial Results and Announces New Clinical Programs
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseas…
National Vision Holdings, Inc. Announces Proposed Private Offering of $350 Million Aggregate Principal Amount of Convertible Senior Notes due 2025
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (the “Company”) today announced that it intends to offer, subject to market and other conditions, $350.0 million aggregate principal amount of Convertible Senior Notes due 2025 …